CIN1

12 registered clinical trials studyying CIN1 — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test NCT06188104	Department of Medical Services Ministry of Public Health of Thailand	Phase 2 / Phase 3
Unknown	Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 M NCT05916911	Catalysis SL	Phase 4
Terminated	A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Ch NCT05584332	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine NCT05371353	Shanghai Bovax Biotechnology Co., Ltd.	—
Recruiting	Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years NCT05027776	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Year NCT04895020	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions NCT04607850	Barinthus Biotherapeutics	Phase 1 / Phase 2
Completed	Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females NCT05372016	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Fem NCT04425291	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Female NCT04422366	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females NCT03676101	Shanghai Bovax Biotechnology Co., Ltd.	Phase 1
Completed	Phase II Evaluation of AHCC for the Eradication of HPV Infections NCT02405533	The University of Texas Health Science Center, Houston	N/A